Thank you, and good evening, everyone. Thank you for joining us at the Alembic Pharmaceuticals Q4 and FY26 investor call.

I am joined with my— with Mr. Krishnan, the CFO, as well as members of the management team.

I will begin with a brief perspective on the environment, performance across our businesses, and strategic actions and a directional view for FY27. Then Krishnan will take you through the financial performance for the quarter and the full year as.

The external environment continues to remain dynamic across the markets. Pricing pressure, competitive intensity, regulatory expectations, and supply chain volatility continue to shape the performance.

In this backdrop, outcomes are being driven less by market tailwinds and more by execution, quality, portfolio choices, cost discipline, and capital allocation. Our approach through the financial year has remained anchored on four clear priorities, which is maintaining our gross margin, protecting the core business, improving operating leverage, and investing selectively in future growth platforms while sharpening operational excellence across all the businesses.

While FY26 includes strategic investments and quarters and some quarter-specific impacts, the broader direction remains clear. We are working to build a stronger and more execution-led platform for the medium term.

Starting with the India business, the business delivered 4% year-on-year growth. The quarter was supported by price-led growth and new launches.

While within the portfolio, specialty therapies and animal healthcare continued to perform relatively better. Specialty growth was supported by gynecology, gastrology, and ophthalmology, while animal healthcare grew strongly and remained an important growth driver.

Focus brands also continued to grow ahead of the broader portfolio, which is important from a quality-of-growth standpoint. The Indore facility is fully operational.

Capacity utilization is improving, and this gives us a better base for supply reliability, logistics, operating efficiency, and future scaling. We also continued the portfolio refresh with new product launches during the quarter, and that should support better growth quality moving forward.

For the full year, India business delivered a growth of 5%. Operationally, the India business is on a firmer footing, and we continue the strength— continue to strengthen the field operations and productivity metrics, focused governance to drive performance.

The inter— the Q4 international business growth remained positive, with US showing growth led by volumes and new launches. The US market— the ex-US markets also continued doing well and grew 20% for the year, while the quarter was muted, but the full year did 20— it grew 20%.

The quarterly performance of ex-US was mainly muted due to a higher base and one-off variances. We're confident of continuing this growth in the ensuing quarters.

We continued to build the pipeline and launch platform. During the quarter, we had six new launches in the US, further ANDA filings and approvals, and progress on partnership-led opportunities.

Our new facilities are getting better utilized, and fo— and we foresee much greater volumes coming out of these facilities in the current year. The broader international business remains a key growth engine, but the business will require sharper product selection, disciplined launch, and tighter control.

On a yearly basis, I think we're pretty happy with the operational outcomes and the way the business has panned out, and I'm confident that moving forward this year will show some of these results. The API deli— business delivered a modest growth in Q4, driven primarily by volumes, while pricing remained a headwind.

This is consistent with the broader market environment we have discussed in earlier calls as well. Our response continues to be on cost improvement, portfolio choices, and capturing opportunities where our development and manufacturing strengths provide a better economic profile.

At a broader level, we are consciously moving towards a more execution-led strategic model. This means higher focus on quality of portfolio and launches, better asset utilization, stronger cost and working capital discipline, and selective investments in platforms.

One part of the strategic pivot is a US branded business approach. We view this as a calibrated strategic entry with a focused go-to-market model and measured investment.

The objective is not rapid scale, but to build a credible and sustainable plat— specialty platform over a period of time. While there are short— there may be a short-term impact on profitability, which should get offset from improved operating leverage in the core business.

In terms of the FY27 directional outlook, we're planning a pragmatic view of the external environment. We are not assuming any major easing in pricing pressure, competition, or supply chain volatility.

At the at the same time, we do see room for performance through internal levers. On the international business, we expect product launches to be phased through the year, with a few meaningful day-one launches in the first couple of quarters and better volumes from the existing portfolio.

We also expect the US branded business to scale up, supported by selective product additions to strengthen the franchise. New product additions, deeper collaborations, and expansion into new territories across Europe and Asia will also support the ex-US markets.

We expect the India business to improve in growth momentum, clo— with and hope to be closer to market growth, with a renewed approach to strengthen focus brands. The international generic business are also likely to grow and a decent amount by low to mid-teen range, and the API business to grow in the high single or low double-digit growth.

This will translate into an overall top line consolidated growth to be in the low double-dige range double-digit range. R&D investments are likely to be around 750 to 800 crores, as we calibrate our portfolio and structurally move towards higher value opportunities, focusing on NCE-1, first to file, and day-one molecules.

While being cautious on global geopolitics and re— related developments, the focus will be not only on growth, but on the quality of growth: better capacity utilization, focused cost savings, working capital, and investing in a differentiated product portfolio. With that, let me hand over to Krishnan, who will take you through the financial performance for the quarter and full year.

Thank you, Pranav. Good evening, everyone.

Let me take you through the financial performance for quarter four and then the full year of 2026, and give you some flavor of FY27 as well. For the quarter, revenue from operations stood at 1,848 crores, up by 4% year-on-year.

The quarter reflected a resilient performance in the top line, supported by new launches in the US, volume-led growth in API, and animal health, partly offset by pricing pressure in certain segments. On the operating front, EBITDA before R&D stood at 455 crores, up by about 8% year-on-year, with core margins almost at 25%, compared to 24% in the previous year same quarter.

This reflects better business mix with slightly better gross margins at 71%, but staying in the previously mentioned range of about 70 to 75%. The EBITDA is after net operating expenses of the US branded business, which started operations in quarter four.

Going forward, we continue to expect the operating leverage improvement to offset the launch-faced margin impact of the US branded business. R&D spending for the quarter was at 209 crores, compared with 151 crores in the same quarter last year, representing 11% of revenue versus 9% last year.

The increase was driven by peptide-related development activities that we did during the quarter, and higher filings in US and ex-US markets compared to the previous year. This, we believe, will help us position for growth in the subsequent periods.

At the profit level, reported profit after tax for the quarter stood at 203 crores. The quarter included an exceptional item of 24 crores, as well as one-time tax adjustments of 101 crores, which is a positive impact relating to MAT credit and tax regimes related adjustments.

From a balance sheet perspective, net working capital stood at 2,000 almost close to 3,000 crores, an increase of about 50 crores versus the December levels, mainly driven by receivables that are not yet due. Gross debt was at 13 61 crores, broadly in line with the December levels.

For the full year, revenue grew by about 10% year-on-year, supported by growth across businesses while absorbing a higher level of investment in R&D and strategic growth initiatives. For FY26, EBITDA before R&D and exceptional items stood at 18 46 crores, representing 25% of revenue and a 20% year-on-year growth.

This reflects growth in the business with better operating leverage across facilities. EBITDA after R&D was at 16% of revenue.

Profit before tax and before exceptional items grew at 10%, broadly reflecting the revenue growth that we had during the year. Reported profit after tax grew at 16% to 675 crores.

Overall, FY26 was a year of steady core operating delivery, alongside higher investment in the pipeline and future growth platforms. While some of these investments have a near-term impact on reported profitability, they are very well aligned to improving medium-term growth quality and strategic positioning.

As Pranav mentioned earlier, our current view for FY27 is directional and based on current visibility. At a consolidated level, we are targeting a low double-digit top line growth, alongside the growth, our focus will remain on margin protection, working capital management, and capital-efficient execution.

We expect margin improvement from core business to give enough headroom to support the launch phase of US branded business. With the launch of Pivya, we expect the branded business franchise to scale up to a meaningful revenue profile in the next few quarters.

We expect capital expenditure for the year to be in the range of 300 to 350 crores, primarily towards capacity debottlenecking and replacement capex. In summary, FY26 reinforced resilience, while FY27, we believe, is focused on maintaining the momentum and winning through execution.

With that, we can now open the floor for questions and answers.

Hi, good evening. Am I audible?

Yes, hi. Am I audible now?

Good evening, everyone. Actually, I would like to ask about the F2 and F3 facilities that remain underutilized pending FDA approvals.

Could you tell us roughly how much cost these facilities are adding to the P&L every year without corresponding revenue, and at what point, whether through our own product approval or the contract manufacturing deals that we are signing, do these facilities start covering their own cost, and what is our internal timeline for that?

We don't give facility-wise breakup, but I can just give you a flavor of what's happening. I think both F2 and F3 are working at a much higher occupancy level than they used to.

We're seeing more meaningful contribution from these. If you see, F3 has multiple lines, right?

I think the ophthalmic line is already chock-a-block. In fact, we're doing an expansion of the ophthalmic line because it's already at full capacity.

In terms of the other two lines in F3, those are also about 40 and 60% capacity utilization for both. In terms of F2, the injectable line and the OSD are both working at a decent amount.

We have a few limited competition opportunities coming, which is what is going to enable them and use these facilities. I think the unabsorbed overheads of both these is not as much of an issue for us.

It's too small a drag in the whole scheme of things, but it's more important for us to keep some headway in these facilities, as we have some important day-one launches coming from these facilities, as well as we're seeing a lot of opportunities for product launches in the next couple of quarters.

Sir. Sir, of the contract manufacturing deals that are already signed for F2, F3, are any of them expected to generate meaningful revenue in '27 itself, or is it more of a FY28 story?

No, it's already started. I think some of the licensing and some of the contract manufacturing is in progress, we'll see part contribution from that in FY27 itself.

Sir. Thank you so much.

Yeah. Hi, sir.

Thanks for taking my question. Sir, can you call out what kind of an impact you saw in the quarter from the investment into the US specialty business?

Is there any drag sitting on the current quarter's margins because of Pivya, and how do you see that going forward as well into FY27? That's my first question.

Yeah.

Thanks, Rahul. There was a drag in the quarter due to the Alembic Therapeutics business, which is which is the sub that has launched the Pivya product.

I'll just, once I finish, I'll let I'll give a direction, and Krishnan will give you further details. There was a drag on the business because of that.

I think the product just got launched in February, we had taken up some of the costs. I think x— I expect another quarter or two of drag the drag coming.

I think by the end of the year, we should start seeing a decent contribution, and we think the last couple of quarters last quarter is when we'll see it starting to turn around. It's an interesting area.

Only thing, it's branded, it does take more time to get the doctor habits to change, but we're quite confident. I think the initial trend is quite healthy, I think, yeah, there will be a drag for another quarter or two.

Krishnan, you know?

On the specific drag, I don't want to put a number to this. Then it becomes a continuous discussion on what's product-level margins that we're going to disclose.

Directionally, if you see, for the full year, we have been able to maintain the margins. For the quarter, there is a bit of drag coming in from the higher R&D spend as well.

I think from a modeling point of view, I would take about 100 to 150 basis points of impact coming from Pivya from the branded business in US. We believe that the margin trajectory for FY27, the core EBITDA margins that comes from the generics formulations and API business should be more than sufficient to offset this impact.

Uh-huh.

Sure, sir. Sir, on R&D, this quarter we saw an increase.

You said that the increase was on account of peptide development. Can you talk about in terms of how do you measure the R&D productivity, particularly for the US business?

Why I say so is because when we were benefiting from certain opportunity in the US, at that point in time our annual R&D spend was around 650 crores, which we had moderated over last couple of years to, let's say, closer to 550 crore kind of an annual number. Now for next year as well, we are again guiding for an increase in R&D spend to 750 to 800 crore.

Just in terms of how do you measure productivity of this R&D investment? Because the high R&D investments are, in fact, dragging your reported EBITDA margin.

Rahul, a good question, actually. A few things.

The Q4 was a little bit of an outlier at 11% of sales. It's a little higher than we would have liked to be.

You're right. Historically, we have gone up to about 14, 15% of revenue as R&D spend, I think, but that we had tapered it down last couple of years.

I think what we're doing is I think the quality of the filings that we're doing is also going up, which has caused some higher spend. Moving forward for the year, I don't expect it to be at 11%.

It'll come back down to about 9% again. I think at an absolute amount, we'll be at that 750-odd crore level.

The reason why this last quarter was a little higher is because we had a few selective complex and peptides developments which were a little more expensive. That's what created a bump.

I think in terms of how we measure it, I think we generally have an IRR for each of our R&D projects. That's what we base our calculations on and what we think makes sense.

As it's getting more competitive, development costs are also getting more expensive, the threshold IRR has come down, but we still see some opportunities, and that's how we're measuring. We're measuring it by opportunity to opportunity.

I think the only way we can grow is if we do have products in the market, and hence we will not go up to the 10 15% levels, but I think this 8 to 9% of revenues is where we'll be at.

Sure, sir. You said you measure R&D productivity through IRR.

Let's say over FY20 to 23 or 24, the R&D spend which we would have done at that point in time, what kind of an IRR would those spends would be generating as of now, if you can share some number?

Sorry. Can you repeat?

Rahul, it's a little tough to say, because I think what's happening is a lot of the filings that happened there, especially from the new facilities, let's say the thin films and everything, they are all late expiry. I think the whole point of the thin films facility was that we were locking in some of the day-ones.

I think you'll see one of them, one launch happening at the end of this quarter. It's a little tough to put it all together.

I think, as I mentioned, the returns came down compared to the returns that we were seeing pre-2020. That's one of the reasons why we tapered down some of the R&D costs as well.

Sure, sir. Last question from my end before I join back the queue: you talked about FY27 guidance from a top line growth perspective.

Can you provide some color in terms of EBITDA margins as well, given that we will have the drag of Pivya this year while on the base business F2, F3 will see an improving utilization by the end of the year? Do you think you can improve margins over FY26 levels,

or

we should be baking in flat margins versus—

It's a good question, Rahul. I think the way I see the business is that the Pivya drag, as I mentioned, by the end of the year, it will not be a drag anymore.

For the rest of it, it'll be covered up by the core business and the business growth that we're seeing. I think we have a few interesting opportunities in the US.

I expect the US business to grow between 10 to 15% at least. The ROW will continue the growth at 15-plus percent.

API will be closer to the 10% growth. India, we hope with some changes we'll get to market growth.

With all this, we'll have a higher contribution. In terms of capex also, we don't have too much this year.

I think we will definitely see an improvement in the margins this year. I expect, as I mentioned, at some point we have to go back up to the 20% kind of EBITDA margins over a two, three-year period.

I expect that this year is going to be a good year that we will start seeing improvement in the margins as well.

Sure, sir. Are we quantifying any number for FY27?

No, no. I'm not giving any guidance.

I think let's see how the first couple of quarters go and then we'll get an idea.

Sure, sir. Thank you.

I will join back the queue.

Thanks for the opportunity, sir. Sir, just on the US guidance of 10 to 15%, these INR terms, right?

So 5, 6% currency depreciation is what is baked in, effectively 7, 8% growth in constant currency terms. Is that the way to think about?

I think again it's not a guidance, but just the way I see the business right now, we'll definitely have growth in the market. That's one way of looking at it.

I'm saying, yeah, in terms of INR terms, I mentioned 10 to 15%.

Sir, on peptide side, what kind of investment we are envisaging in terms of R&D and in terms of capex separately?

Capex is all done. I think we've already completed the capex for the peptides.

This was a filing that had to happen, with the batches and it's important, it's a big filing, hence we had some cost related to that. Moving forward, we will not have as many such costs.

I think as and when a product comes into development. This was an outlier because the batches were conducted and there was a NCE-1 filing.

Sir,

how many filings are we sort of thinking on peptides, maybe over next 12 months?

We've got a couple. I think the portfolio is about five to six that we have.

I think two of them are filed already, and the rest are going on.

Sorry for my ignorance, but how much capex we have already done for peptides?

I think, Krishnan, was 50 crores? I think we haven't given a disclosure, but it's a part of our already ongoing existing API facility.

That's where we've done the peptide API investment. In terms of the formulation, it gets taken care of by our regular formulation capacity that we have.

Okay. This is not a dedicated capex for peptide that is.

No, it is part of a facility, and an ongoing facility where we've fine-tuned one block.

Sir, on API side, at a portfolio level, have you seen sort of price increases, given the crude-linked derivative, to say, solvents have seen sharp increase in prices? Subsequently, are we seeing API prices moving up for us?

Okay. No, no.

Good question, Tushar. I'll just give you a background.

I think just, as you said, I'll give you a background about our API business. Our API business, it's a pretty high-margin business and it's quite a profitable business for us, because one of the reasons is we are at a much higher price.

I think we don't compete at the bottom level with whether Chinese or the dropping prices. I think, we do have premium prices on the markets.

That's one. Our values, the compliance and the supply chain resilience, right?

We have good prices on the API side in the market. Secondly, I think in terms of are we seeing increase in some solvents?

Yes, we're seeing it. Have we passed it on?

No, it's still not a materially big issue for us. As we generally do carry a higher bit of inventory, and that's helped us out right now.

I think we're okay with utilizing the inventory. We do have higher prices, so that's not as much of a concern for us at this stage.

Understood. Probably considering the current inventory is for at least next—

We're okay. I think it's not impacting any margins for us.

Okay. As far as branded business goes, post-launch, of course, it's too short a time period, but any sort of either in terms of increasing prescription or any color you would like to throw?

I don't have any data that I can share with all of you, but I can just say it's just been only Feb end, right, that we launched. It's only been a couple of months, and I think this is where we're visiting the doctors.

We've started off with a smaller field force, reaching out to doctors only in high-prescription territory for UTIs. We're seeing a good trend.

We're seeing a good feedback. I think it'll be another quarter or two till we are more comfortable giving out more metrics on this.

Lastly, just on a broader question, sir, in terms of capital allocation, the peptides is one area where we've done reasonable investment over last one to two years. Now this branded business is there.

Likewise, in any other areas where the capital allocation would happen in, let's say, over FY27, '28, or these are the key areas to focus on now?

I think what's going to happen is in terms of capital allocation, if you see in terms of capex, we're broadly done with all our capex. Even the branded business, it doesn't entail any capex.

I think the only investment was in licensing of the product. On the branded side, we will in-license few more products.

We're seeing some opportunities that we can build into Alembic Therapeutics to grow the branded business. That is one part.

Second is our R&D investments will continue, though in a measured manner to see where it happens. That's it.

I think these are the two broad areas. Basically, it'll be R&D and the branded business.

All right. Thanks.

That's it from my side. Thank you.

Participants, if

Thank you for joining us on the quarter four and full year conference call. If you have got any follow-up questions, please reach out to the investor relations team.

Thank you.